BTEK.L vs. BRK-B
BTEK.L (iShares Nasdaq US Biotechnology UCITS ETF) is Health & Biotech Equities fund tracking the NASDAQ Biotechnology TR USD, while BRK-B (Berkshire Hathaway Inc.) is a stock. Over the past 5 years, BTEK.L returned 5.85%/yr vs 11.54%/yr for BRK-B. At a 0.21 correlation, their price movements are largely independent.
Performance
BTEK.L vs. BRK-B - Performance Comparison
Loading charts...
Different Trading Currencies
BTEK.L is traded in GBP, while BRK-B is traded in USD. To make them comparable, the BRK-B values have been converted to GBP using the latest available exchange rates.
Returns By Period
In the year-to-date period, BTEK.L achieves a 4.86% return, which is significantly higher than BRK-B's -4.39% return.
BTEK.L
- 1D
- 3.56%
- 1M
- 2.25%
- YTD
- 4.86%
- 6M
- 2.70%
- 1Y
- 43.15%
- 3Y*
- 10.19%
- 5Y*
- 5.85%
- 10Y*
- —
BRK-B
- 1D
- 0.69%
- 1M
- 3.76%
- YTD
- -4.39%
- 6M
- -5.55%
- 1Y
- -1.57%
- 3Y*
- 10.51%
- 5Y*
- 11.54%
- 10Y*
- 13.78%
BTEK.L vs. BRK-B - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BTEK.L iShares Nasdaq US Biotechnology UCITS ETF | 4.86% | 23.81% | -0.32% | 0.33% | -1.55% | 0.90% | 23.11% | 21.63% | -6.34% | -3.31% |
BRK-B Berkshire Hathaway Inc. | -4.39% | 2.99% | 29.31% | 9.69% | 15.59% | 30.17% | -0.64% | 6.71% | 9.11% | 1.48% |
Correlation
The correlation between BTEK.L and BRK-B is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.08 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.18 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.17 |
Correlation (All Time) Calculated using the full available price history since Oct 25, 2017 | 0.21 |
The correlation between BTEK.L and BRK-B shifts across timeframes, from 0.08 (1 year) to 0.21 (all time), reflecting how their relationship changes across market environments.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BTEK.L vs. BRK-B — Risk / Return Rank
BTEK.L
BRK-B
BTEK.L vs. BRK-B - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) and Berkshire Hathaway Inc. (BRK-B). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BTEK.L | BRK-B | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.35 | ||
| Sortino ratioReturn per unit of downside risk | +3.17 | ||
| Omega ratioGain probability vs. loss probability | 1.38 | 1.00 | +0.38 |
| Calmar ratioReturn relative to maximum drawdown | 6.23 | -0.13 | +6.37 |
| Martin ratioReturn relative to average drawdown | 17.55 | -0.29 | +17.84 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| BTEK.L | BRK-B | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.24 | -0.10 | +2.35 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.29 | 0.69 | -0.40 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.70 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.31 | 0.59 | -0.28 |
Drawdowns
BTEK.L vs. BRK-B - Drawdown Comparison
The maximum BTEK.L drawdown since its inception was -30.86%, smaller than the maximum BRK-B drawdown of -37.92%. Use the drawdown chart below to compare losses from any high point for BTEK.L and BRK-B.
Loading charts...
Drawdown Indicators
| BTEK.L | BRK-B | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -30.86% | -37.92% | +7.06% |
Max Drawdown (1Y)Largest decline over 1 year | -6.89% | -11.88% | +4.99% |
Max Drawdown (3Y)Largest decline over 3 years | -26.34% | -17.26% | -9.08% |
Max Drawdown (5Y)Largest decline over 5 years | -30.86% | -20.84% | -10.02% |
Max Drawdown (10Y)Largest decline over 10 years | — | -21.44% | — |
Current DrawdownCurrent decline from peak | -1.86% | -13.90% | +12.04% |
Average DrawdownAverage peak-to-trough decline | -10.04% | -7.39% | -2.65% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.45% | 5.50% | -3.05% |
Volatility
BTEK.L vs. BRK-B - Volatility Comparison
iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) has a higher volatility of 6.91% compared to Berkshire Hathaway Inc. (BRK-B) at 3.86%. This indicates that BTEK.L's price experiences larger fluctuations and is considered to be riskier than BRK-B based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BTEK.L | BRK-B | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.91% | 3.86% | +3.05% |
Volatility (6M)Calculated over the trailing 6-month period | 14.67% | 11.95% | +2.72% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.14% | 15.41% | +3.73% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.08% | 16.90% | +3.18% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 21.71% | 19.85% | +1.86% |
Dividends
BTEK.L vs. BRK-B - Dividend Comparison
Neither BTEK.L nor BRK-B has paid dividends to shareholders.
Frequently Asked Questions
BTEK.L and BRK-B have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for BTEK.L and BRK-B
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer